Trial Profile

Comparison of olanzapine versus fosaprepitant when given in combination with palonosetron and dexamethasone in preventing nausea and vomiting in highly emetogenic chemotherapy (HEC) and radiation therapy receiving patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jun 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosaprepitant (Primary) ; Cisplatin; Dexamethasone; Olanzapine; Palonosetron
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use

18 Jun 2015 New trial record
02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com